National trends in use and costs of oral anticancer drugs in France: An 8‐year population‐based study
- 3 August 2017
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 26 (10) , 1233-1241
Abstract
Purpose: During the last decade, many oral anticancer drugs (OAcDs) have been marketed, providing interesting but potentially costly pharmaceutical alternatives to intravenous treatments. This study aims to provide updated information on their use and costs.Methods: A cross‐sectional yearly repeated study was conducted from 2006 to 2014 using the representative sample of the French national health care insurance system claims database (EGB). OAcD use was described for each year, among prevalent (ie, patients with at least 1 OAcD reimbursement) and incident users (ie, patients with no OAcD reimbursement within the prior year) and according to their pharmacological classes (Hormone Therapy [HT], Cytotoxic Therapy [CT], Targeted Therapy [TT], and others). Demographic characteristics were described for both users; comorbidities and direct medical costs were described for incident users only.Results: The yearly prevalence and incidence of OAcD use, mainly represented by HT, remained stable from 2006 to 2014 (1.2%; 0.4%). Compared with users of other OAcD classes, the proportion of TT users substantially increased over the 8‐year study period (+9.3%), and TT incident users had more severe comorbidities at treatment initiation. The health expenditures were the most important in TT users with median monthly medical direct costs varying from 2995€ to 4968€ per patient between 2006 and 2014.Conclusion: With the development of new OAcDs, the TTs use reaches a wider population of patients but is responsible for increasing health expenditures.Keywords
This publication has 19 references indexed in Scilit:
- World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015Advances in Nutrition, 2016
- Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011Journal of Clinical Oncology, 2015
- Patterns of use of oral anticancer treatments in France: a Retrospective Analysis of Cancer Treatments given ORally from 2004 to 2012 (Re-ACTOR study)Current Medical Research and Opinion, 2014
- National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011Health Affairs, 2014
- Anticancer oral therapy: Emerging related issuesCancer Treatment Reviews, 2010
- French national health insurance information system and the permanent beneficiaries sampleRevue D'Épidémiologie Et de Santé Publique, 2010
- Patient adherence and persistence with oral anticancer treatmentCA: A Cancer Journal for Clinicians, 2009
- Effective oral chemotherapy for breast cancer: pillars of strengthAnnals of Oncology, 2007
- Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic ApplicationCancer Investigation, 2005
- Oral cancer treatment: developments in chemotherapy and beyondBritish Journal of Cancer, 2002